However, tamoxifen-resistant tumors eventually emerged from minimal residual disease within the tumor beds in both PDX models after a period of discontinued tamoxifen treatment (Fig. 4, D and E), recapitulating another important phenomenon associated with the clinical progression of aggressive ER+ breast cancer. Here, ESR1 is linked to neoplasm.